28Jan 2023
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

Efanesoctocog alfa provides high sustained factor VIII activity by overcoming the von Willebrand factor–imposed half-life ceiling. The efficacy, safety, and pharmacokinetics of efanesoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with severe hemophilia A are unclear. The results of this study demonstrated that in patients with severe hemophilia A, once-weekly efanesoctocog alfa provided superior bleeding prevention to prestudy prophylaxis, normal to near-normal factor VIII activity, and improvements in physical health, pain, and joint health.

  • #family health

Like

Save

Share